Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Breast Neoplasms 2Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioma 1Glioblastoma 1Disease 1Dermatofibrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Temozolomide 69Bevacizumab 40Radiotherapy 22Magnetic Resonance Spectroscopy 20Irinotecan 17Specimen Handling 10Carboplatin 10Carmustine 9X-Rays 7Radiation 7olaparib 6Surgical Procedures, Operative 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Nivolumab 6Everolimus 6Cyclophosphamide 6Biopsy 6trametinib 5Thalidomide 5Cisplatin 5pembrolizumab 4palbociclib 4fluorodopa F 18 4erdafitinib 4dabrafenib 4Lomustine 4Etoposide 4Drug Therapy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioma × Quality of Life × Clear all
NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
42 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡